577 related articles for article (PubMed ID: 16556028)
1. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
3. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
4. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
[TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma.
Ginsberg JP; de Alava E; Ladanyi M; Wexler LH; Kovar H; Paulussen M; Zoubek A; Dockhorn-Dworniczak B; Juergens H; Wunder JS; Andrulis IL; Malik R; Sorensen PH; Womer RB; Barr FG
J Clin Oncol; 1999 Jun; 17(6):1809-14. PubMed ID: 10561219
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
7. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
8. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
9. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
10. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
[TBL] [Abstract][Full Text] [Related]
11. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.
Toretsky JA; Erkizan V; Levenson A; Abaan OD; Parvin JD; Cripe TP; Rice AM; Lee SB; Uren A
Cancer Res; 2006 Jun; 66(11):5574-81. PubMed ID: 16740692
[TBL] [Abstract][Full Text] [Related]
12. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
[TBL] [Abstract][Full Text] [Related]
13. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
Abaan OD; Levenson A; Khan O; Furth PA; Uren A; Toretsky JA
Oncogene; 2005 Apr; 24(16):2715-22. PubMed ID: 15782144
[TBL] [Abstract][Full Text] [Related]
14. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.
Aryee DN; Niedan S; Kauer M; Schwentner R; Bennani-Baiti IM; Ban J; Muehlbacher K; Kreppel M; Walker RL; Meltzer P; Poremba C; Kofler R; Kovar H
Cancer Res; 2010 May; 70(10):4015-23. PubMed ID: 20442286
[TBL] [Abstract][Full Text] [Related]
16. STAT3 is activated in a subset of the Ewing sarcoma family of tumours.
Lai R; Navid F; Rodriguez-Galindo C; Liu T; Fuller CE; Ganti R; Dien J; Dalton J; Billups C; Khoury JD
J Pathol; 2006 Apr; 208(5):624-32. PubMed ID: 16463269
[TBL] [Abstract][Full Text] [Related]
17. Promiscuous partnerships in Ewing's sarcoma.
Sankar S; Lessnick SL
Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma.
Bachmaier R; Aryee DN; Jug G; Kauer M; Kreppel M; Lee KA; Kovar H
Oncogene; 2009 Mar; 28(9):1280-4. PubMed ID: 19151750
[TBL] [Abstract][Full Text] [Related]
19. Recombinant EWS-FLI1 oncoprotein activates transcription.
Uren A; Tcherkasskaya O; Toretsky JA
Biochemistry; 2004 Oct; 43(42):13579-89. PubMed ID: 15491164
[TBL] [Abstract][Full Text] [Related]
20. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
